Intra-Cellular Therapies Investor Relations Material

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system. These diseases include schizophrenia and bipolar disorder, as well as other disorders such as depression and sleep disorders. The company's lead product candidate is latrepirdine, an orally available small molecule designed to be an efficacious anti-schizophrenia drug with a favorable safety profile and improved tolerability compared with existing antipsychotic treatments.